Marker Therapeutics, Inc. (MRKR)
1.49
+0.02
(+1.36%)
USD |
NASDAQ |
Dec 31, 16:00
1.48
-0.01
(-0.67%)
After-Hours: 20:00
Marker Therapeutics Research and Development Expense (TTM): 14.74M for Sept. 30, 2025
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| ADMA Biologics, Inc. | 3.776M |
| Neurocrine Biosciences, Inc. | 936.90M |
| AIM ImmunoTech, Inc. | 3.826M |
| Protalix Biotherapeutics, Inc. | 18.06M |
| Armata Pharmaceuticals, Inc. | 26.10M |